In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model-Reference-Cited by-同舟云学术

In Vivo Efficacy of Meropenem with a Novel Non-β-Lactam–β-Lactamase Inhibitor, Nacubactam, against Gram-Negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model

Published:2018-09 Issue:9 Volume:62 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Monogue Marguerite L.¹,Giovagnoli Sara¹,Bissantz Caterina²³,Zampaloni Claudia²⁴,Nicolau David P.¹⁵

Affiliation:

1. Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, Connecticut, USA

2. Division of Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

3. Division of Pharmaceutical Science, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

4. Division of Immunology, Inflammation and Infectious Diseases, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland

5. Division of Infectious Diseases, Hartford Hospital, Hartford, Connecticut, USA

Abstract

Urinary tract infections (UTIs) are a tremendous burden on the health care system due to the vast number of infections resulting in antibiotic therapy and/or hospitalization. Additionally, these infections are frequently caused by multidrug-resistant (MDR) organisms, limiting the availability of effective antimicrobials.

Funder

HHS | Biomedical Advanced Research and Development Authority

Roche

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02596-17

Reference23 articles.

1. Clinical and economic implications of urinary tract infections

2. Urinary Tract Infection Syndromes